IP Library Granted Patent US 8,496,651
Granted Patent B2
US 8,496,651 · App. 12/360,726 · Granted Jul 30, 2013

System and method for refractive surgery with augmentation by intrastromal corrective procedure

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,496,651
App. No.
12/360,726
Granted
Jul 30, 2013
Kind
B2
Abstract

A system and method are provided for an ophthalmic surgical procedure to provide a refractive correction for an eye. Specifically, the procedure is indicated when the desired refractive correction “d reqd ” exceeds the capability of a correction achievable when corneal tissue is only ablated. In accordance with the present invention, an optimized refractive correction “d 1 ” is accomplished by the ablation of corneal tissue (e.g. by a PRK or LASIK procedure). The optimized correction is then followed by a complementary refractive correction “d 2 ” wherein stromal tissue is weakened with Laser Induced Optical Breakdown (LIOB). Together, the optimized refractive correction (ablation) and the complementary refractive correction (LIOB) equal the desire refractive correction (d reqd =d 1 +d 2 ).

Claims (24)

1. A method for combining corneal tissue removal with an intrastromal redistribution of biomechanical stresses to achieve a predetermined refractive correction for an eye, the method comprising the steps of:

ablating a predetermined volume of corneal tissue to attain an optimized refractive correction for the eye (d 1 ); and

weakening stromal tissue, by making incisions within the stromal layer below the ablated volume, to incorporate a complementary refractive correction for the eye (d 2 ) along with the optimized refractive correction, to achieve a required refractive correction (d reqd ), wherein the optimized refractive correction is less than the required refractive correction (d 1 <d reqd ).

2. A method as recited in claim 1 wherein d reqd is more than about 3 diopters.

3. A method as recited in claim 2 wherein d 2 is approximately in a range of two to two and one half diopters.

4. A method as recited in claim 1 wherein the ablating step is accomplished prior to the weakening step.

5. A method as recited in claim 1 wherein the ablating step is accomplished as a PRK procedure.

6. A method as recited in claim 1 wherein the ablating step is accomplished as a LASIK procedure.

7. A method as recited in claim 1 wherein the weakening step is accomplished using a femtosecond laser for causing Laser Induced Optical Breakdown (LIOB) of stromal tissue.

8. A method as recited in claim 1 wherein the ablating step is accomplished using an excimer laser.

9. A method for combining corneal tissue removal with an intrastromal redistribution of biomechanical stresses to achieve a predetermined refractive correction for an eye, the method comprising the steps of:

establishing a required diopter correction for the eye “d reqd ” to achieve the predetermined refractive correction;

determining a first maximum diopter correction for the eye “d 1max ”, wherein d 1max is achievable by removing corneal tissue from the eye, and wherein d reqd is greater than d 1max ;

ascertaining a second maximum diopter correction for the eye “d 2max ”, wherein d 2max is achievable by changing a biomechanical stress distribution in the stroma of the eye, and wherein d reqd is greater than d 2max ;

ablating corneal tissue to achieve a first actual diopter correction “d 1actual ”, wherein d 1actual is less than d 1max ; and

performing Laser Induced Optical Breakdown (LIOB), within the stromal layer below the ablated tissue to achieve a second actual diopter correction “d 2actual ”, wherein d 2actual is less than d 2max , and further wherein d 1actual +d 2actual equals d reqd (d reqd =d 1actual +d 2actual ).

10. A method as recited in claim 9 wherein d reqd is more than about 3 diopters.

11. A method as recited in claim 10 wherein d 2max is approximately in a range of two to two and one half diopters.

12. A method as recited in claim 9 wherein the ablating step is accomplished prior to the performing step.

13. A method as recited in claim 9 wherein the ablating step is accomplished as a PRK procedure.

14. A method as recited in claim 9 wherein the ablating step is accomplished as a LASIK procedure.

15. A method as recited in claim 9 wherein the performing step is accomplished using a femtosecond laser for causing Laser Induced Optical Breakdown (LIOB) of stromal tissue.

16. A method as recited in claim 9 wherein the ablating step is accomplished using an excimer laser.

17. A method as recited in claim 9 wherein the ablating step is accomplished prior to the performing step and is separated therefrom by a time interval of approximately three weeks.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →